Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethanolic extract of red okra pods (EEROP) is a plant-derived research compound obtained from the pods of red okra (*Abelmoschus esculentus* L. Moench) using ethanol as a solvent. Primarily investigated by researchers at Universitas Airlangga in Indonesia, this complex natural product mixture is being studied for its potential anti-cancer properties. Preclinical studies have demonstrated its efficacy in various cancer models, including breast, cervical, and colorectal cancers. Its mechanism of action involves the inhibition of the Wnt/β-catenin signaling pathway, modulation of oncogenes such as MYC, TYMS, and MDM2, and the induction of apoptosis and aberrant spindle segregation. As a crude extract, it contains a variety of phytochemicals that contribute to its multi-targeted biological activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethanolic extract of red okra pods.